TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 2.80nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 3.5nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 3.70nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 5.20nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 5.60nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 7.20nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 8.20nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 11nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Galderma Research & Development
US Patent
Galderma Research & Development
US Patent
Affinity DataIC50: 11.4nMAssay Description:Activity of the compounds was investigated using TACE (ADAM17) isolated enzyme. The screening of ADAM17 inhibitors was performed with a profluorescen...More data for this Ligand-Target Pair
Affinity DataIC50: 4.46E+3nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 ??L containing 1% DMSO. Recombinant Human catalytic domains of...More data for this Ligand-Target Pair
Affinity DataIC50: 4.63E+3nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 ??L containing 1% DMSO. Recombinant Human catalytic domains of...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 ??L containing 1% DMSO. Recombinant Human catalytic domains of...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 ??L containing 1% DMSO. Recombinant Human catalytic domains of...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 ??L containing 1% DMSO. Recombinant Human catalytic domains of...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 ??L containing 1% DMSO. Recombinant Human catalytic domains of...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 ??L containing 1% DMSO. Recombinant Human catalytic domains of...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 ??L containing 1% DMSO. Recombinant Human catalytic domains of...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:The enzymatic reaction was performed in 384-well microplates with a final volume of 10 ??L containing 1% DMSO. Recombinant Human catalytic domains of...More data for this Ligand-Target Pair